undamentalytics Newsletter
Sign in

Immunitybio, Inc. revenue

Immunitybio, Inc.'s revenue was $113m in fiscal 2025, up 668.3% on the year before. Since fiscal 2013 ($600,000) it has grown at a compound 54.8% a year. Over the last twelve months it was $166m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1100002110115113166
Growth on the year before—+6.8%−63.2%−81.4%+2.3%+4.4%+>999%−72.5%+54.4%−74.3%+159.2%+>999%+668.3%—
Gross profit—————————0115113165
Gross margin—————————100.0%100.0%100.0%99.3%99.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $113M 99.7% ▲ 698.5%
Other $306,000 0.3% ▼ 48.6%
Geography
Region Revenue Share YoY
United States $113M 99.8% ▲ 695.1%
Europe $278,000 0.2% ▼ 47.6%

From Immunitybio, Inc.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Immunitybio, Inc. $166m 192.9% 554.3%
Nuvation Bio Inc. $170m 1083.6% —
Beam Therapeutics Inc. $156m 158.9% 24.9%
Arbutus Biopharma Corp $182m 1078.8% 97.6%
Karyopharm Therapeutics Inc. $147m 6.8% 0.1%
Urogen Pharma Ltd. $189m 100.3% 37.6%

Compare with peers

Head to head: IBRX vs NUVBBEAM vs IBRXABUS vs IBRXIBRX vs KPTI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunitybio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunitybio, Inc.